Bank of New York Mellon Corp Increases Stock Holdings in Inogen, Inc. (NASDAQ:INGN)

Bank of New York Mellon Corp increased its stake in shares of Inogen, Inc. (NASDAQ:INGN) by 23.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 126,461 shares of the medical technology company’s stock after purchasing an additional 24,082 shares during the period. Bank of New York Mellon Corp’s holdings in Inogen were worth $1,160,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. BNP Paribas Financial Markets lifted its stake in shares of Inogen by 13.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 42,137 shares of the medical technology company’s stock worth $409,000 after acquiring an additional 5,131 shares during the period. Geode Capital Management LLC lifted its position in Inogen by 1.1% in the third quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company’s stock valued at $5,377,000 after purchasing an additional 5,921 shares during the period. Quarry LP purchased a new stake in Inogen in the 3rd quarter valued at approximately $59,000. Ieq Capital LLC acquired a new position in Inogen during the 4th quarter worth approximately $94,000. Finally, Verition Fund Management LLC purchased a new position in shares of Inogen during the 3rd quarter worth approximately $106,000. 89.94% of the stock is currently owned by hedge funds and other institutional investors.

Inogen Price Performance

Shares of INGN opened at $7.37 on Tuesday. Inogen, Inc. has a 1-year low of $6.14 and a 1-year high of $13.33. The stock has a market cap of $195.53 million, a price-to-earnings ratio of -3.28 and a beta of 1.15. The firm has a 50 day simple moving average of $9.69 and a 200-day simple moving average of $9.64.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on INGN. StockNews.com downgraded Inogen from a “buy” rating to a “hold” rating in a research note on Wednesday, February 26th. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a report on Wednesday, February 26th.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.